Maze Therapeutics has had impressive results since its initial public offering in January, and CEO Jason Coloma expects that momentum to continue as the company works to bring its kidney disease treatment to market.
Maze Therapeutics, a clinical-stage biopharmaceutical company, went public on the Nasdaq stock exchange on January 31 at $16.12 per share (IPO price of $16). It has recently been trading above $32.
The company was also named to CNBC’s list of top-performing San Francisco-based companies. To find the name, CNBC looked at companies headquartered in the region with a market capitalization of more than $500 million. We then screened the top performers over the past three months via FactSet.
During this period, Maze stock price increased by 83.65%.
Koroma told CNBC that the company is focused on developing and discovering new drugs for kidney disease, which affects about 37 million people in the U.S. alone. One of them was former Jets player Nick Mangold, who just passed away Saturday from complications from kidney disease.
“There is a shortage, so to speak, of new drugs for these patients, and that’s where Maze Therapeutics fits in,” Koroma said in an interview with Brian Sullivan.
The company’s latest trial was on something called MZE782, an oral SLC6A19 inhibitor aimed at treating chronic kidney disease and phenylketonuria (PKU). Phase 1 trial results were positive. Maze Therapeutics plans to begin Phase 2 trials in 2026. The goal after that is to conduct so-called pivotal studies that, if successful, would allow the company to commercialize a treatment, Koroma said.
Maze is well-capitalized and won’t necessarily need to find a larger pharmaceutical partner to ultimately bring its drug to market, he said.
“We can discover those specific drugs, develop them, and hopefully get them to patients,” Koroma said. “We’re just focused on execution right now.”
